CRO Communiqué
Keeping you informed about CRO progress
May 2010
Top Enrolling Physicians for Grant Year - (6/1/09 – 5/31/10)
|
Dr. Raju |
17 Credit Registrations |
2 No Credit |
19 Total |
|
Dr. Holden |
16 Credit Registrations |
2 No Credit |
18 Total |
|
Dr. Bonebrake |
16 Credit Registrations |
0 No Credit |
16 Total |
|
Dr. Ellis |
12 Credit Registrations |
0 No Credit |
12 Total |
|
Dr. Tiriveedhi |
11 Credit Registrations |
1 No Credit |
12 Total |
|
Dr. Williams |
11 Credit Registrations |
1 No Credit |
12 Total |
April was the third straight good enrollment month for CRO. We had 24 enrollments to 17 different studies during April. Cox had another excellent month with 14 of our enrollments coming from this location. We now have 109.8 treatment credits. Our treatment credits target is 130 for the year. Our control credits are at 50.5 and our target is 90. Our grant year ends on May 31st. We are hoping for another good month so we can meet our target treatment credits of 130, but it is doubtful we will be able to meet our target control credits of 90 for this grant year. Special thanks to all enrolling physicians. Above are our enrollment stars.
Research Discovery
An update of the results of the Study of Raloxifene and Tamoxifen, (NSABP P-2 STAR trial in
breast cancer prevention) shows that the drug raloxifene (initially used to prevent and treat osteoporosis in postmenopausal women) was more effective against noninvasive breast cancer, caused significantly less endometrial cancer and was significantly less toxic than tamoxifen. Although raloxifene was slightly less effective against invasive breast cancer, it still maintained strong efficacy after 81 months of follow-up.
Cancer Research for the Ozarks participated in the STAR Study, one of the largest breast cancer prevention clinical trials ever conducted. STAR enrolled 19,490 postmenopausal women who were at increased risk for the disease in the follow-up study. At CRO, 101 women were enrolled in the trial between July 1999 when it opened and January 2005 when it closed. We continue to follow-up with these ladies on an annual basis. This is a great study with very significant results for breast cancer prevention.
NCI Cooperative Group Programs
For the past 50 years, NCI’s 10 Cooperative Groups have been very successful in developing new and improved therapies…however, many stakeholders have expressed concerns that the program is falling short of its potential. As a result NCI asked the
Institute of
Medicine to assess the state of cancer clinical trials, review the Cooperative Group Program and provide advice for improvements. Their recommendations are found in a report entitled, “A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program”. The link to the
Institute of
Medicine’s Report on the Cooperative Groups is at
http://www.iom.edu/Reports/2010/A-National-Cancer-Clinical-Trials-System-for-the-21st-Century-Reinvigorating-the-NCI-Cooperative.aspx This report has great merit for the research world and CRO. I encourage you to take a few minutes and review the 4 page report.
Dr. Carolla Auditor for Moffitt Research Base
CRO’s Principal Investigator, Robert Carolla MD, was in
Tampa,
Florida auditing Moffitt research Base on April 27th & 28th. Information he gains from his auditing experience is an asset to CRO in preparing for our Cooperative Group audits and assists us to become an even better CCOP.
More